---
title: "Absci | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 318 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295575256.md"
datetime: "2026-08-11T20:18:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295575256.md)
  - [en](https://longbridge.com/en/news/295575256.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295575256.md)
generator: "portal-rs"
---

# Absci | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 318 K

Revenue: As of FY2026 Q2, the actual value is USD 318 K, missing the estimate of USD 931.67 K.

EPS: As of FY2026 Q2, the actual value is USD -0.21, missing the estimate of USD -0.1974.

EBIT: As of FY2026 Q2, the actual value is USD -33.17 M.

### Financial Performance for the Three Months Ended June 30, 2026

#### Revenue

Absci Corporation’s partner program revenue was $0.3 million for the three months ended June 30, 2026, a decrease from $0.6 million for the same period in 2025. For the six months ended June 30, 2026, partner program revenue was $0.5 million, compared to $1.8 million for the six months ended June 30, 2025.

#### Operating Costs and Profitability

Research and development expenses increased to $22.6 million for the three months ended June 30, 2026, up from $20.5 million in the prior year, driven by the advancement of Absci Corporation’s internal programs, including direct costs for external preclinical and clinical development of ABS-201, partially offset by decreased personnel-related costs. Selling, general, and administrative expenses rose to $9.2 million from $8.5 million for the three months ended June 30, 2025, primarily due to stock-based compensation and other administrative costs. Total operating expenses reached $34.5 million, an increase from $32.0 million for the three months ended June 30, 2025. The operating loss for the quarter was - $34.2 million, compared to - $31.4 million in the same period last year. Net loss was - $33.2 million, compared to - $30.6 million for the three months ended June 30, 2025. Net loss per share (Basic and Diluted) was - $0.21, an improvement from - $0.24 for the three months ended June 30, 2025.

### Balance Sheet as of June 30, 2026

#### Cash and Investments

As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $201.1 million, an increase from $125.7 million as of March 31, 2026. Cash and cash equivalents were $107.9 million, up from $20.0 million as of December 31, 2025. Marketable securities were $93.3 million, compared to $124.3 million as of December 31, 2025.

#### Unique Metrics/Highlights

Absci Corporation completed a $100 million underwritten offering, which included a $40 million strategic equity investment from Eli Lilly & Company. The net proceeds from this offering were $93.6 million, contributing to the cash, cash equivalents, and marketable securities as of June 30, 2026.

### Outlook / Guidance

Absci Corporation expects to report interim proof-of-concept data from the HEADLINE trial for pattern hair loss in the second half of 2026 and full proof-of-concept data in early 2027. The company plans to initiate a Phase 2 clinical trial for endometriosis in the fourth quarter of 2026, with potential proof-of-concept data anticipated in the second half of 2027. Based on current projections, Absci Corporation believes its cash, cash equivalents, and marketable securities are sufficient to fund operating plans into the second half of 2028.

### Related Stocks

- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)

## Related News & Research

- [Absci (ABSI) Could Be 32% Undervalued Following ABS 201 Data And Earnings](https://longbridge.com/en/news/295686913.md)
- [AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained](https://longbridge.com/en/news/295652271.md)
- [Absci director Mary T Szela acquires 12,900 common shares for $148,866](https://longbridge.com/en/news/291839359.md)
- [Absci Q2 revenue falls and misses analyst expectations](https://longbridge.com/en/news/295574634.md)
- [Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/290920860.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**